Novartis Launches Extavia For Practice In MS Market, Preparing For FTY720

Novartis is launching its interferon beta-1b product Extavia not to be competitive in the multiple sclerosis market so much as to get a sales infrastructure up and running for its late-stage oral MS drug fingolimod (FTY720), Pharmaceuticals CEO Joe Jimenez said during the firm's 2008 year-end earnings call Jan. 28